Yesterday’s Q3 earnings report did not include any significant surprises. As expected, the costs were on the rise during Q3, but a bit less than we had anticipated. However, we are not making any model revisions. Instead, we want to highlight the importance of the upcoming January MERECA study follow-up, since if the survival data have continued to develop in a positive direction we see room to raise our valuation.